Pfizer Inc (PFE)
Pfizer Inc (PFE) carries a ŷRobot AI score of 48 out of 100. The model's fair value estimate is $27.84, 4.7% below the last close of $29.22. The chart signal reads S-Sell.
| Metric | PFE |
|---|---|
| AI score | 48 / 100 |
| Chart signal | S-Sell |
| Fair value estimate | $27.84 |
| Upside to fair value | -4.7% |
| Previous close | $29.22 |
| P/E | 37.53 |
| Price / sales | 2.52 |
| Market cap | $161.19B |
| EPS | 0.76 |
| Revenue growth | -15.3% |
| 1-year price change | 4.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about PFE
Is PFE overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates Pfizer Inc (PFE) at $27.84 against a last close of $29.22, implying 4.7% downside to the model's estimate.
Is PFE's chart signal bullish or bearish?
The chart-signal model classifies PFE as Bearish as of Oct 14, 2026, with a signal score of -0.17 on a -1 to 1 scale.
What is PFE's ŷRobot AI score?
PFE scores 48 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is PFE stock expensive on P/E and P/S?
PFE trades at 37.5 times earnings and 2.5 times sales as of Oct 14, 2026.
What does PFE's seasonal forecast show?
ŷRobot's seasonal forecast curve for PFE reads +0.6% at 30 days, +4.1% at 90 days, and +4.0% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is PFE growing?
Pfizer Inc's revenue growth is -15.3% and free-cash-flow growth is -2.8% on the latest reported figures.
PFE chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.